RA Drug May Help Treat Recalcitrant Eczema
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
Powered by five integrated technologies, the multi-platform is designed to support a range of treatments for various skin types and conditions.